10,670 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by Wolverine Asset Management LLC

Wolverine Asset Management LLC bought a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,670 shares of the company’s stock, valued at approximately $782,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Emerald Advisers LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $15,560,000. Soleus Capital Management L.P. acquired a new position in Mirum Pharmaceuticals during the second quarter worth $15,201,000. Bank of New York Mellon Corp boosted its position in Mirum Pharmaceuticals by 101.1% during the second quarter. Bank of New York Mellon Corp now owns 496,061 shares of the company’s stock worth $25,245,000 after purchasing an additional 249,331 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in Mirum Pharmaceuticals during the second quarter worth $11,071,000. Finally, JPMorgan Chase & Co. grew its holdings in Mirum Pharmaceuticals by 66.8% in the second quarter. JPMorgan Chase & Co. now owns 480,276 shares of the company’s stock valued at $24,441,000 after purchasing an additional 192,340 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Citizens Jmp lifted their price target on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, December 19th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an “outperform” rating in a report on Monday, December 8th. HC Wainwright reiterated a “buy” rating and issued a $102.00 price target (up from $81.00) on shares of Mirum Pharmaceuticals in a research report on Tuesday. Finally, Morgan Stanley raised their price objective on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $102.00.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $91.05 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The firm has a market cap of $4.68 billion, a PE ratio of -105.87 and a beta of 0.48. The firm has a 50 day simple moving average of $75.05 and a 200-day simple moving average of $69.27. Mirum Pharmaceuticals, Inc. has a 1-year low of $36.88 and a 1-year high of $93.70.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.30) EPS. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.